Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SCOPUS BIOPHARMA INC
No Price
30.04.2026 20:00
Current Prices from SCOPUS BIOPHARMA INC
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
UTC
SCPS
USD
30.04.2026 20:00
0,0004 USD
0,00 USD
NASDAQ
SCPS
USD
28.04.2026 14:14
0,0004 USD
-
Share Float & Liquidity
Free Float81,32 %
Shares Float34,22 M
Shares Outstanding42,08 M
Company Profile for SCOPUS BIOPHARMA INC Share
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
